trioxsalen has been researched along with Anemia, Fanconi in 14 studies
Trioxsalen: Pigmenting photosensitizing agent obtained from several plants, mainly Psoralea corylifolia. It is administered either topically or orally in conjunction with ultraviolet light in the treatment of vitiligo.
lactone : Any cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
antipsoriatic : A drug used to treat psoriasis.
trioxsalen : 7H-Furo[3,2-g]chromen-7-one in which positions 2, 5, and 9 are substituted by methyl groups. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered orally in conjunction with UV-A for phototherapy treatment of vitiligo. After photoactivation it creates interstrand cross-links in DNA, inhibiting DNA synthesis and cell division, and can lead to cell injury; recovery from the cell injury may be followed by increased melanisation of the epidermis.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (35.71) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Voter, AF | 1 |
| Manthei, KA | 1 |
| Keck, JL | 1 |
| Fendrick, JL | 1 |
| Hallick, LM | 1 |
| Poll, EH | 1 |
| Arwert, F | 1 |
| Kortbeek, HT | 1 |
| Eriksson, AW | 1 |
| Kano, Y | 1 |
| Fujiwara, Y | 1 |
| Papadopoulo, D | 6 |
| Laquerbe, A | 4 |
| Guillouf, C | 2 |
| Moustacchi, E | 6 |
| Fuscoe, JC | 1 |
| Hang, B | 1 |
| Yeung, AT | 1 |
| Lambert, MW | 2 |
| Kumaresan, KR | 1 |
| Sala-Trepat, M | 2 |
| Rouillard, D | 1 |
| Escarceller, M | 1 |
| Akkari, YM | 1 |
| Bateman, RL | 1 |
| Reifsteck, CA | 1 |
| D'Andrea, AD | 1 |
| Olson, SB | 1 |
| Grompe, M | 1 |
| Porfirio, B | 1 |
| Coppey, J | 1 |
| Lopez, B | 1 |
| Averbeck, D | 1 |
14 other studies available for trioxsalen and Anemia, Fanconi
| Article | Year |
|---|---|
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
Topics: Antineoplastic Agents; DNA Damage; DNA Helicases; DNA Repair; Drug Screening Assays, Antitumor; Fanc | 2016 |
Psoralen photoinactivation of herpes simplex virus: monoadduct and cross-link repair by xeroderma pigmentosum and Fanconi's anemia cells.
Topics: Anemia, Aplastic; Cell Line; Cross-Linking Reagents; DNA Repair; Fanconi Anemia; Furocoumarins; Huma | 1984 |
Fanconi anaemia cells are not uniformly deficient in unhooking of DNA interstrand crosslinks, induced by mitomycin C or 8-methoxypsoralen plus UVA.
Topics: Cell Line; Cross-Linking Reagents; DNA Repair; Fanconi Anemia; Furocoumarins; Humans; Methoxsalen; M | 1984 |
Dyskeratosis congenita: survival, sister-chromatid exchange and repair following treatments with crosslinking agents.
Topics: Cell Survival; Cells, Cultured; Cross-Linking Reagents; Crossing Over, Genetic; Diagnosis, Different | 1982 |
Molecular spectrum of mutations induced at the HPRT locus by a cross-linking agent in human cell lines with different repair capacities.
Topics: Base Sequence; Cell Line; Cross-Linking Reagents; DNA; DNA Repair; Fanconi Anemia; Humans; Hypoxanth | 1993 |
The molecular mechanism underlying formation of deletions in Fanconi anemia cells may involve a site-specific recombination.
Topics: Base Sequence; Cells, Cultured; Conserved Sequence; DNA Mutational Analysis; Exons; Fanconi Anemia; | 1995 |
Mutagenic processing of psoralen monoadducts differ in normal and Fanconi anemia cells.
Topics: Base Sequence; Cells, Cultured; DNA; DNA Mutational Analysis; DNA Repair; Exons; Fanconi Anemia; Hum | 1993 |
A damage-recognition protein which binds to DNA containing interstrand cross-links is absent or defective in Fanconi anemia, complementation group A, cells.
Topics: Base Sequence; Binding, Competitive; Cell Line, Transformed; Cross-Linking Reagents; DNA; DNA Damage | 1993 |
Fanconi anemia, complementation group A, cells are defective in ability to produce incisions at sites of psoralen interstrand cross-links.
Topics: Adenosine Triphosphate; Base Sequence; Cell Line; Cross-Linking Reagents; DNA; DNA Damage; DNA Repai | 2000 |
Arrest of S-phase progression is impaired in Fanconi anemia cells.
Topics: Cell Line; Cross-Linking Reagents; DNA Adducts; DNA Replication; Fanconi Anemia; G2 Phase; Humans; M | 2000 |
The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase.
Topics: Cell Line; Chromosome Breakage; Cross-Linking Reagents; DNA; DNA Repair; Fanconi Anemia; Fibroblasts | 2001 |
Mutagenic response of Fanconi's anemia cells from a defined complementation group after treatment with photoactivated bifunctional psoralens.
Topics: Anemia, Aplastic; Cell Survival; Fanconi Anemia; Furocoumarins; Humans; Hypoxanthine Phosphoribosylt | 1990 |
Multiplicity reactivation and mutagenesis of trimethylpsoralen-damaged herpes virus in normal and Fanconi's anaemia cells.
Topics: Adult; Anemia, Aplastic; Child; Dose-Response Relationship, Drug; Fanconi Anemia; Fibroblasts; Furoc | 1989 |
Repair of 4,5',8-trimethylpsoralen plus light-induced DNA damage in normal and Fanconi's anemia cell lines.
Topics: Anemia, Aplastic; Cell Line; Cell Survival; DNA; DNA Damage; DNA Repair; Fanconi Anemia; Furocoumari | 1988 |